Advertisement

Archives of Virology

, Volume 164, Issue 2, pp 349–357 | Cite as

Molecular diagnosis of occult hepatitis C virus infection in Iranian injection drug users

  • Maryam Sheikh
  • Farah Bokharaei-SalimEmail author
  • Seyed Hamidreza Monavari
  • Angila Ataei-Pirkooh
  • Maryam Esghaei
  • Najmeh Moradi
  • Roghayeh Babaei
  • Atousa Fakhim
  • Hossein Keyvani
Original Article
  • 46 Downloads

Abstract

Occult HCV infection (OCI) has been described as the presence of hepatitis C virus (HCV) genomic RNA in hepatocytes and/or peripheral blood mononuclear cell (PBMC) specimens and the lack of HCV genomic RNA and anti-HCV antibodies (Abs) in plasma samples. Injection drug users (IDUs) are the most important high-risk group for infection with blood-borne viruses, particularly HCV. The purpose of this study was to determine the presence of OCI in IDUs. A prospective cross-sectional study of 126 consecutive Iranian IDUs was performed from March 2017 to January 2018. PBMCs were separated from blood samples from the participants, and after extraction of the viral RNA from the plasma and PBMC specimens, HCV RNA was detected in the samples using RT-nested PCR by amplification of the 5′-NTR of HCV. HCV genotyping was carried out using restriction a fragment length polymorphism (RFLP) assay. The viral RNA was amplified using RT-nested PCR with specific primers for the NS5B gene, and the PCR products were sequenced to confirm the results obtained by HCV RNA detection and HCV genotyping. Out of the 126 IDUs studied, 105 (83.3%) were negative for anti-HCV Abs and HCV RNA in plasma samples, whereas HCV RNA was detected in the PBMC samples of six (5.7%) participants, indicating that these individuals had OCI. Moreover, HCV genomic RNA was detected in PBMC samples from five (23.8%) of the 21 IDUs studied who were positive for anti-HCV Abs and negative for HCV genomic RNA in plasma specimens. These IDUs also had OCI. The HCV genotypes in the PBMC samples from the subjects with OCI were determined. Six (54.5%) subjects were infected with HCV subtype 3a, and five (45.5%) were infected with HCV subtype 1a. This study showed that 8.7% of the Iranian IDUs had OCI, and therefore, a study focusing on the diagnosis of OCI in these individuals can be valuable and informative.

Notes

Acknowledgements

The authors of the current research would like to thank all the injection drug users who enrolled in this study.

Funding

This project was financially supported by Research Deputy of Iran University of Medical Sciences (Grant Number: 27948), and it also was extracted from a thesis written by Maryam Sheikh, who was financially supported by a grant from Iran University of Medical Sciences (Thesis Number: 9411541003).

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interest to declare.

References

  1. 1.
    Fields B, Knipe D, Howley P (2013) Fields virology. Wolters Kluwer Health/Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar
  2. 2.
    World Health Organization Global Health (2018) HCV [online]. http://www.who.int/news-room/fact-sheets/detail/hepatitis-c
  3. 3.
    Vescovo T, Refolo G, Vitagliano G, Fimia GM, Piacentini M (2016) Molecular mechanisms of hepatitis C virus–induced hepatocellular carcinoma. Clin Microbiol Infect 22(10):853–861CrossRefGoogle Scholar
  4. 4.
    Hellard M, Sacks-Davis R, Gold J (2009) Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 49(4):561–573CrossRefGoogle Scholar
  5. 5.
    Razali K, Thein HH, Bell J, Cooper-Stanbury M, Dolan K, Dore G et al (2007) Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend 91(2):228–235CrossRefGoogle Scholar
  6. 6.
    Roy E, Alary M, Morissette C, Leclerc P, Boudreau J, Parent R et al (2007) High hepatitis C virus prevalence and incidence among Canadian intravenous drug users. Int J Std Aids 18(1):23–27CrossRefGoogle Scholar
  7. 7.
    Daniels D, Grytdal S, Wasley A (2009) Surveillance for acute viral hepatitis—United States, 2007. Morb Mortal Wkly Rep Surveill Summ 58(3):1–27Google Scholar
  8. 8.
    Zamani S, Ichikawa S, Nassirimanesh B, Vazirian M, Ichikawa K, Gouya MM et al (2007) Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy 18(5):359–363CrossRefGoogle Scholar
  9. 9.
    Sarkari B, Eilami O, Khosravani A, Sharifi A, Tabatabaee M, Fararouei M (2012) High prevalence of hepatitis C infection among high risk groups in Kohgiloyeh and Boyerahmad Province. Southwest Iran. Arch Iran Med. 15(5):271–274Google Scholar
  10. 10.
    Alavian SM, Mirahmadizadeh A, Javanbakht M, Keshtkaran A, Heidari A, Mashayekhi A et al (2013) Effectiveness of methadone maintenance treatment in prevention of hepatitis C virus transmission among injecting drug users. Hepat Mon 13(8):e12411CrossRefGoogle Scholar
  11. 11.
    Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D et al (2011) Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378(9791):571–583CrossRefGoogle Scholar
  12. 12.
    Bastani MN, Bokharaei-Salim F, Keyvani H, Esghaei M, Monavari SH, Ebrahimi M et al (2016) Prevalence of occult hepatitis C virus infection in Iranian patients with beta thalassemia major. Arch Virol 161(7):1899–1906CrossRefGoogle Scholar
  13. 13.
    Bokharaei-Salim F, Keyvani H, Esghaei M, Zare-Karizi S, Dermenaki-Farahani SS, Hesami-Zadeh K et al (2016) Prevalence of occult hepatitis C virus infection in the Iranian patients with human immunodeficiency virus infection. J Med Virol 88(11):1960–1966CrossRefGoogle Scholar
  14. 14.
    Farahani M, Bokharaei-Salim F, Ghane M, Basi A, Meysami P, Keyvani H (2013) Prevalence of occult hepatitis C virus infection in Iranian patients with lymphoproliferative disorders. J Med Virol 85(2):235–240CrossRefGoogle Scholar
  15. 15.
    Pham TN, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI (2004) Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 78(11):5867–5874CrossRefGoogle Scholar
  16. 16.
    Castillo I, Pardo M, Bartolome J, Ortiz-Movilla N, Rodriguez-Inigo E, de Lucas S et al (2004) Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 189(1):7–14CrossRefGoogle Scholar
  17. 17.
    Carreño V (2014) Seronegative occult hepatitis C virus infection: Clinical implications. J Clin Virol 61(3):315–320CrossRefGoogle Scholar
  18. 18.
    Rezaee-Zavareh MS, Einollahi B (2014) Treatment of occult hepatitis C virus infection: does it need special attention. Hepat Mon 14(7):e16665Google Scholar
  19. 19.
    Bokharaei-Salim F, Keyvani H, Monavari SH, Alavian SM, Madjd Z, Toosi MN et al (2011) Occult hepatitis C virus infection in Iranian patients with cryptogenic liver disease. J Med Virol 83(6):989–995CrossRefGoogle Scholar
  20. 20.
    Keyvani H, Bokharaei-Salim F, Monavari SH, Esghaei M, Nassiri Toosi M, Fakhim S et al (2013) Occult hepatitis C virus infection in candidates for liver transplant with cryptogenic cirrhosis. Hepat Mon 13(8):e11290CrossRefGoogle Scholar
  21. 21.
    Carreno V, Bartolome J, Castillo I, Quiroga JA (2012) New perspectives in occult hepatitis C virus infection. World J Gastroenterol 18(23):2887–2894CrossRefGoogle Scholar
  22. 22.
    Sadeghi F, Bokharaei-Salim F, Salehi-Vaziri M, Monavari SH, Alavian SM, Salimi S et al (2014) Associations between human TRIM22 gene expression and the response to combination therapy with Peg-IFNα-2a and ribavirin in Iranian patients with chronic hepatitis C. J Med Virol 86(9):1499–1506CrossRefGoogle Scholar
  23. 23.
    Dehghani-Dehej F, Sarvari J, Esghaei M, Hosseini SY, Garshasbi S, Kalantari S, et al (2017) Presence of different hepatitis C virus genotypes in plasma and peripheral blood mononuclear cell samples of iranian patients with HIV infection. J Med VirolGoogle Scholar
  24. 24.
    Pohjanpelto P, Lappalainen M, Widell A, Asikainen K, Paunio M (1996) Hepatitis C genotypes in Finland determined by RFLP. Clin Diagn Virol. 7(1):7–16CrossRefGoogle Scholar
  25. 25.
    Bokharaei-Salim F, Keyvani H, Salehi-Vaziri M, Sadeghi F, Monavari SH, Mehrnoush L et al (2014) Mutations in the NS5A gene of hepatitis C virus subtype 1b and response to peg-IFNalpha-2a/RBV combination therapy in Azerbaijani patients. Arch Virol 159(11):2893–2899CrossRefGoogle Scholar
  26. 26.
    Ji H, Kozak RA, Biondi MJ, Pilon R, Vallee D, Liang BB et al (2015) Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations. Virology 477:1–9CrossRefGoogle Scholar
  27. 27.
    Telles PR, Bastos FI, Guydish J, Inciardi JA, Surratt HL, Pearl M et al (1997) Risk behavior and HIV seroprevalence among injecting drug users in Rio de Janeiro, Brazil. AIDS 11(Suppl 1):S35–S42Google Scholar
  28. 28.
    Dan M, Rock M, Lilos P, Shany SB (1993) Seroepidemiology of hepatitis B and D virus infection among intravenous drug addicts in Israel. Int J Epidemiol 22(1):140–143CrossRefGoogle Scholar
  29. 29.
    Ebeling F (1994) Importance of hepatitis C virus infection in Europe and North America. Curr Stud Hematol Blood Transfus 61:164–181CrossRefGoogle Scholar
  30. 30.
    Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR et al (2010) Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis 14(Suppl 3):e113–e116CrossRefGoogle Scholar
  31. 31.
    Zaghloul H, El-Sherbiny W (2010) Detection of occult hepatitis C and hepatitis B virus infections from peripheral blood mononuclear cells. Immunol Invest 39(3):284–291CrossRefGoogle Scholar
  32. 32.
    Idrees M, Lal A, Malik FA, Hussain A, Rehman I, Akbar H et al (2011) Occult hepatitis C virus infection and associated predictive factors: the Pakistan experience. Infect Genet Evol 11(2):442–445CrossRefGoogle Scholar
  33. 33.
    Thongsawat S, Maneekarn N, Kuniholm MH, Pantip C, Thungsuputi A, Lumlertkul D et al (2008) Occult hepatitis C virus infection during an outbreak in a hemodialysis unit in Thailand. J Med Virol 80(5):808–815CrossRefGoogle Scholar
  34. 34.
    Naghdi R, Ranjbar M, Bokharaei-Salim F, Keyvani H, Savaj S, Ossareh S et al (2017) Occult hepatitis C infection among hemodialysis patients: a prevalence study. Ann Hepatol 16(4):510–513CrossRefGoogle Scholar
  35. 35.
    Barril G, Castillo I, Arenas MD, Espinosa M, Garcia-Valdecasas J, Garcia-Fernandez N et al (2008) Occult hepatitis C virus infection among hemodialysis patients. J Am Soc Nephrol 19(12):2288–2292CrossRefGoogle Scholar
  36. 36.
    Baid-Agrawal S, Berg T (2014) Reply to: “underestimation of occult hepatitis C virus infection in chronic haemodialysis and kidney transplant patients”. J Hepatol 61(5):1185–1186CrossRefGoogle Scholar
  37. 37.
    Castillo I, Martinez-Ara J, Olea T, Bartolome J, Madero R, Hernandez E et al (2014) High prevalence of occult hepatitis C virus infection in patients with primary and secondary glomerular nephropathies. Kidney Int 86(3):619–624CrossRefGoogle Scholar
  38. 38.
    Youssef SS, Nasr AS, El Zanaty T, El Rawi RS, Mattar MM (2012) Prevalence of occult hepatitis C virus in egyptian patients with chronic lymphoproliferative disorders. Hepat Res Treat 2012:429784Google Scholar
  39. 39.
    Gatserelia L, Sharvadze L, Karchava M, Dolmazashvili E, Tsertsvadze T (2014) Occurrence of occult HCV infection among Hiv infected patients in Georgia. Georgian Med News 226:37–41Google Scholar
  40. 40.
    De Marco L, Manzini P, Trevisan M, Gillio-Tos A, Danielle F, Balloco C et al (2012) Prevalence and follow-up of occult HCV infection in an Italian population free of clinically detectable infectious liver disease. PloS One 7(8):e43541CrossRefGoogle Scholar
  41. 41.
    Helaly GF, Elsheredy AG, El Basset Mousa AA, Ahmed HK, Oluyemi AE (2017) Seronegative and occult hepatitis C virus infections in patients with hematological disorders. Arch Virol 162(1):63–69CrossRefGoogle Scholar
  42. 42.
    Lin H, Chen X, Zhu S, Mao P, Zhu S, Liu Y et al (2016) Prevalence of occult hepatitis C virus infection among blood donors in Jiangsu, China. Intervirology 59(4):204–210CrossRefGoogle Scholar
  43. 43.
    De Marco L, Gillio-Tos A, Fiano V, Ronco G, Krogh V, Palli D et al (2009) Occult HCV infection: an unexpected finding in a population unselected for hepatic disease. PloS One 4(12):e8128CrossRefGoogle Scholar
  44. 44.
    Sugden PB, Pham TN, Ratnarajah S, Cameron B, Bull R, White PA et al (2013) Rare occurrence of occult hepatitis C virus in apparently uninfected injecting drug users: a two-centre, masked, case-control study. J Viral Hepat 20(10):725–728CrossRefGoogle Scholar
  45. 45.
    Giannini C, Giannelli F, Zignego AL (2006) Association between mixed cryoglobulinemia, translocation (14;18), and persistence of occult HCV lymphoid infection after treatment. Hepatology 43(5):1166–1167 (author reply 7–8) CrossRefGoogle Scholar
  46. 46.
    Nicot F, Kamar N, Mariame B, Rostaing L, Pasquier C, Izopet J (2010) No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients. Transpl Int 23(6):594–601CrossRefGoogle Scholar
  47. 47.
    Richiardi L, De Marco L, Gillio-Tos A, Merletti F, Fiano V, Palli D et al (2010) Persistent infection by HCV and EBV in peripheral blood mononuclear cells and risk of non-Hodgkin’s lymphoma. Cancer Epidemiol 34(6):709–712CrossRefGoogle Scholar
  48. 48.
    Pisaturo M, Guastafierro S, Filippini P, Tonziello G, Sica A, Di Martino F et al (2013) Absence of occult HCV infection in patients experiencing an immunodepression condition. Infez Med 21(4):296–301Google Scholar
  49. 49.
    Welker MW, Zeuzem S (2009) Occult hepatitis C: how convincing are the current data? Hepatology 49(2):665–675CrossRefGoogle Scholar
  50. 50.
    Eslamifar A, Ramezani A, Ehteram H, Razeghi E, Ahmadi F, Amini M et al (2015) Occult hepatitis C virus infection in Iranian hemodialysis patients. J Nephropathol 4(4):116–120Google Scholar
  51. 51.
    Telfer P, Devereux H, Savage K, Scott F, Dhillon A, Dusheiko G et al (1995) Chronic hepatitis C virus infection in haemophilic patients: clinical significance of viral genotype. Thromb Haemost 74(5):1259–1264CrossRefGoogle Scholar
  52. 52.
    Di Liberto G, Roque-Afonso AM, Kara R, Ducoulombier D, Fallot G, Samuel D et al (2006) Clinical and therapeutic implications of hepatitis C virus compartmentalization. Gastroenterology 131(1):76–84CrossRefGoogle Scholar
  53. 53.
    Freitas SZ, Teles SA, Lorenzo PC, Puga MAM, Tanaka TSO, Thomaz DY et al (2014) HIV and HCV coinfection: prevalence, associated factors and genotype characterization in the midwest region of Brazil. Rev Inst Med Trop São Paulo 56(6):517–524CrossRefGoogle Scholar
  54. 54.
    Weber R, Ruppik M, Rickenbach M, Spörri A, Furrer H, Battegay M et al (2013) Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 14(4):195–207CrossRefGoogle Scholar
  55. 55.
    Hsieh MH, Tsai JJ, Hsieh MY, Huang CF, Yeh ML, Yang JF et al (2014) Hepatitis C virus infection among injection drug users with and without human immunodeficiency virus co-infection. PloS One 9(4):e94791CrossRefGoogle Scholar
  56. 56.
    Zhang Z, Yao Y, Wu W, Feng R, Wu Z, Cun W et al (2013) Hepatitis C virus genotype diversity among intravenous drug users in Yunnan Province, Southwestern China. PloS One 8(12):e82598CrossRefGoogle Scholar
  57. 57.
    Jamalidoust M, Namayandeh M, Asaei S, Aliabadi N, Ziyaeyan M (2014) Determining hepatitis C virus genotype distribution among high-risk groups in Iran using real-time PCR. World J Gastroenterol 20(19):5897–5902CrossRefGoogle Scholar
  58. 58.
    Hajiani E, Hashemi SJ, Masjedizadeh A, Shayesteh AA, Jalali F (2011) Genotypic analysis of hepatitis C virus in khuzestan province, southwestern iran. Middle East J Dig Dis 3(2):126–130Google Scholar
  59. 59.
    Samimi-Rad K, Nasiri Toosi M, Masoudi-Nejad A, Najafi A, Rahimnia R, Asgari F et al (2012) Molecular epidemiology of hepatitis C virus among injection drug users in Iran: a slight change in prevalence of HCV genotypes over time. Arch Virol 157(10):1959–1965CrossRefGoogle Scholar
  60. 60.
    Bokharaei Salim F, Keyvani H, Amiri A, Jahanbakhsh Sefidi F, Shakeri R, Zamani F (2010) Distribution of different hepatitis C virus genotypes in patients with hepatitis C virus infection. World J Gastroenterol 16(16):2005–2009CrossRefGoogle Scholar
  61. 61.
    Blackard JT, Smeaton L, Hiasa Y, Horiike N, Onji M, Jamieson DJ et al (2005) Detection of hepatitis C virus (HCV) in serum and peripheral-blood mononuclear cells from HCV-monoinfected and HIV/HCV–coinfected persons. J Infect Dis 192(2):258–265CrossRefGoogle Scholar
  62. 62.
    Backmund M, Meyer K, Von Zielonka M, Eichenlaub D (2001) Treatment of hepatitis C infection in injection drug users. Hepatology 34(1):188–193CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2018

Authors and Affiliations

  • Maryam Sheikh
    • 1
  • Farah Bokharaei-Salim
    • 1
    • 2
    Email author
  • Seyed Hamidreza Monavari
    • 1
  • Angila Ataei-Pirkooh
    • 1
  • Maryam Esghaei
    • 1
  • Najmeh Moradi
    • 2
  • Roghayeh Babaei
    • 2
  • Atousa Fakhim
    • 3
  • Hossein Keyvani
    • 1
  1. 1.Department of Virology, School of MedicineIran University of Medical SciencesTehranIran
  2. 2.Iran University of Medical SciencesTehranIran
  3. 3.Department of Architectural Engineering, Faculty of EngineeringIslamic Azad University, South Tehran BranchTehranIran

Personalised recommendations